{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:17:43Z","timestamp":1789107463579,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We conducted a phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) and KPd with daratumumab (Dara-KPd) in relapsed\/refractory multiple myeloma. The primary end points were identification of a maximum tolerated dose (MTD) of KPd for phase 1, and rates of overall response (ORR) and near complete response (nCR) after 4 cycles of KPd and Dara-KPd, respectively, for phase 2. The MTD for KPd was carfilzomib 20\/27\u00a0mg\/m2 on days 1, 2, 8, 9, 15, and 16 (cycles 1-8) and days 1, 2, 15, and 16 for cycles 9 and beyond; oral pomalidomide 4\u00a0mg on days 1 to 21; and oral dexamethasone 40\u00a0mg weekly in 28-day cycles. Sixty-six patients received KPd, including 34 at the MTD. The ORR after 4 cycles of KPd at the MTD was 27\/34 (79%; 95% confidence interval [CI], 62%-91%), meeting the statistical threshold for efficacy. At a median follow-up of 44\u00a0months, the median progression-free survival (PFS) was 13 months and overall survival (OS) 44\u00a0months. Twenty-eight patients received Dara-KPd. The rate of nCR or better after 4 cycles was 11\/28 (39%; 95%\u00a0CI, 22%-59%), meeting the statistical threshold for efficacy. As the best response to Dara-KPd, the ORR was 25\/28 (89%) and the rate of measurable residual disease negativity by flow cytometry (10\u22125) was 17\/26 (65%). At a median follow-up of 26\u00a0months, the median PFS and OS for Dara-KPd were not reached. Dara-KPd induced deeper and more durable responses than KPd without compromising safety in a predominantly high-risk, lenalidomide-refractory population, warranting further evaluation of this quadruplet. This trial is registered at www.clinicaltrials.gov as #NCT01665794.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008866","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T20:24:39Z","timestamp":1676060679000},"page":"5703-5712","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[{"name":"2Karmanos Cancer Center, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"3Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Cole","sequence":"additional","affiliation":[{"name":"4Michigan State University, East Lansing, MI"},{"name":"5University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[{"name":"6Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-3430","authenticated-orcid":false,"given":"Andrew T.","family":"Stefka","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Major","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-2374","authenticated-orcid":false,"given":"Andrew","family":"Kin","sequence":"additional","affiliation":[{"name":"2Karmanos Cancer Center, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-4328","authenticated-orcid":false,"given":"Kent","family":"Griffith","sequence":"additional","affiliation":[{"name":"5University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagoda","family":"Jasielec","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"},{"name":"7Janssen Pharmaceuticals, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"9","key":"2023101015204887500_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2023101015204887500_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023101015204887500_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023101015204887500_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"2023101015204887500_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023101015204887500_bib6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023101015204887500_bib7","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023101015204887500_bib8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10245","key":"2023101015204887500_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2023101015204887500_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023101015204887500_bib11","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2023101015204887500_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023101015204887500_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10192","key":"2023101015204887500_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2023101015204887500_bib15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023101015204887500_bib16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"2023101015204887500_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"issue":"26","key":"2023101015204887500_bib18","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A\u00a0phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023101015204887500_bib19","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2023101015204887500_bib20","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2023101015204887500_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","article-title":"Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study","volume":"32","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2023101015204887500_bib22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2021-149423","article-title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with first progression of multiple myeloma refractory to bortezomib and lenalidomide. Final report of the EMN011\/HOVON114 trial","volume":"138","author":"Sonneveld","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023101015204887500_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2023101015204887500_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10214","key":"2023101015204887500_bib25","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"10292","key":"2023101015204887500_bib26","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023101015204887500_bib27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.annonc.2022.04.013","article-title":"VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)","volume":"33","author":"Moreau","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"2023101015204887500_bib28","doi-asserted-by":"crossref","first-page":"S403","DOI":"10.1016\/S2152-2650(22)01586-5","article-title":"MM-064 updated progression-free survival and depth of response in IKEMA, a randomized phase 3 trial of isatuximab, carfilzomib, and dexamethasone (Isa-Kd) versus Kd in relapsed multiple myeloma","volume":"22","author":"Martin","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2023101015204887500_bib29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023101015204887500_bib30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"25","key":"2023101015204887500_bib31","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"2023101015204887500_bib32","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2022.40.16_suppl.8012","article-title":"A\u00a0phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma","volume":"40","author":"Yee","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5703\/2083664\/blooda_adv-2022-008866-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5703\/2083664\/blooda_adv-2022-008866-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:26:13Z","timestamp":1696951573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5703\/494454\/Phase-1-2-study-of-carfilzomib-pomalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":32,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008866","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}